Publication:
HIGH-DOSE EPIRUBICIN IN CHEMOTHERAPY REFRACTORY NONSEMINOMATOUS GERM-CELL CANCER - A PHASE-II STUDY

Simple item page
dc.contributor.authorsSTOTER, G; AKDAS, A; FOSSA, SD; KAYE, SB; VANGROENINGEN, CJ; RENARD, J; VANGLABBEKE, M
dc.date.accessioned2022-04-25T00:09:58Z
dc.date.accessioned2026-01-10T18:07:38Z
dc.date.available2022-04-25T00:09:58Z
dc.date.issued1992
dc.description.abstractEighteen patients with progressive disseminated, platinum-resistant germ cell tumors were treated with epirubicin 35 mg/m2, every 3 weeks. One patient had stable disease, 17 developed progression. Myelosuppression was dose-limiting. One patient died of neutropenic septicemia. High-dose epirubicin is not active against platinum-resistant germ cell cancer.
dc.identifier.doi10.1093/oxfordjournals.annonc.a058266
dc.identifier.issn0923-7534
dc.identifier.pubmed1323325
dc.identifier.urihttps://hdl.handle.net/11424/263552
dc.identifier.wosWOS:A1992JE85400019
dc.languageeng
dc.publisherKLUWER ACADEMIC PUBL
dc.relation.ispartofANNALS OF ONCOLOGY
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectEPIRUBICIN
dc.subjectGERM CELL CANCER
dc.subjectTESTICULAR CANCER
dc.subjectTESTICULAR CANCER
dc.titleHIGH-DOSE EPIRUBICIN IN CHEMOTHERAPY REFRACTORY NONSEMINOMATOUS GERM-CELL CANCER - A PHASE-II STUDY
dc.typeother
dc.type.subnote
dspace.entity.typePublication
oaire.citation.endPage578
oaire.citation.issue7
oaire.citation.startPage577
oaire.citation.titleANNALS OF ONCOLOGY
oaire.citation.volume3

Files

Collections

Araştırma Çıktıları